Nitrosamine Impurities: A Persistent Regulatory Challenge in Drug Development
Explore how FDA and EMA guidance is shaping nitrosamine risk assessments and why robust strategies are essential to avoid major objections in regulatory submissions.
Explore how FDA and EMA guidance is shaping nitrosamine risk assessments and why robust strategies are essential to avoid major objections in regulatory submissions.